Technical Analysis for IMUX - Immunic, Inc.

Grade Last Price % Change Price Change
grade C 17.11 -0.70% -0.12
IMUX closed down 0.7 percent on Thursday, October 29, 2020, on 50 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical IMUX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Fell Below 50 DMA Bearish -0.70%
Bollinger Band Squeeze Range Contraction -0.70%
Crossed Above 50 DMA Bullish -2.28%
Bollinger Band Squeeze Range Contraction -2.28%
Oversold Stochastic Weakness -2.28%
Stochastic Buy Signal Bullish 2.27%
Bollinger Band Squeeze Range Contraction 2.27%
Older End-of-Day Gignals for IMUX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Resistance about 11 hours ago
Rose Above 10 DMA about 11 hours ago
Rose Above Previous Day's High about 12 hours ago
Rose Above 50 DMA about 12 hours ago
10 DMA Resistance about 12 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Medicine Biopharmaceutical Clinical Medicine Immunotherapy Autoimmune Diseases Multiple Sclerosis Psoriasis Ulcerative Colitis Abdominal Pain Crohn's Disease Primary Sclerosing Cholangitis Relapsing Remitting Multiple Sclerosis Mayo Clinic

Is IMUX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.39
52 Week Low 4.19
Average Volume 495,391
200-Day Moving Average 12.42
50-Day Moving Average 17.37
20-Day Moving Average 18.43
10-Day Moving Average 17.56
Average True Range 1.28
ADX 17.05
+DI 21.21
-DI 23.63
Chandelier Exit (Long, 3 ATRs ) 16.94
Chandelier Exit (Short, 3 ATRs ) 19.87
Upper Bollinger Band 20.72
Lower Bollinger Band 16.14
Percent B (%b) 0.21
BandWidth 24.86
MACD Line -0.20
MACD Signal Line 0.05
MACD Histogram -0.2518
Fundamentals Value
Market Cap 354.49 Million
Num Shares 20.7 Million
EPS -11.31
Price-to-Earnings (P/E) Ratio -1.51
Price-to-Sales 0.00
Price-to-Book 4.48
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.29
Resistance 3 (R3) 19.31 18.60 18.92
Resistance 2 (R2) 18.60 18.05 18.59 18.80
Resistance 1 (R1) 17.86 17.71 17.51 17.84 18.68
Pivot Point 17.15 17.15 16.98 17.14 17.15
Support 1 (S1) 16.41 16.60 16.06 16.39 15.54
Support 2 (S2) 15.70 16.26 15.69 15.42
Support 3 (S3) 14.96 15.70 15.30
Support 4 (S4) 14.94